CEL-SCI (CVM) Competitors $3.96 -0.21 (-5.04%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.97 +0.01 (+0.25%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVM vs. COEP, TPST, NRSN, CVKD, CGTX, ALXO, CARA, TENX, OVID, and CYTHShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Coeptis Therapeutics (COEP), Tempest Therapeutics (TPST), NeuroSense Therapeutics (NRSN), Cadrenal Therapeutics (CVKD), Cognition Therapeutics (CGTX), ALX Oncology (ALXO), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Ovid Therapeutics (OVID), and Cyclo Therapeutics (CYTH). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. Its Competitors Coeptis Therapeutics Tempest Therapeutics NeuroSense Therapeutics Cadrenal Therapeutics Cognition Therapeutics ALX Oncology Cara Therapeutics Tenax Therapeutics Ovid Therapeutics Cyclo Therapeutics Coeptis Therapeutics (NASDAQ:COEP) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends. Do insiders & institutionals have more ownership in COEP or CVM? 13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 12.1% of CEL-SCI shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 9.9% of CEL-SCI shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer COEP or CVM? In the previous week, Coeptis Therapeutics and Coeptis Therapeutics both had 1 articles in the media. Coeptis Therapeutics' average media sentiment score of 0.00 equaled CEL-SCI'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CEL-SCI 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, COEP or CVM? Coeptis Therapeutics has a beta of -0.63, indicating that its stock price is 163% less volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Is COEP or CVM more profitable? CEL-SCI's return on equity of -238.05% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -282.39% -127.23% CEL-SCI N/A -238.05%-104.65% Which has higher valuation and earnings, COEP or CVM? Coeptis Therapeutics is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis TherapeuticsN/AN/A-$10.88M-$5.80-1.84CEL-SCIN/AN/A-$26.92M-$12.61-0.31 SummaryCoeptis Therapeutics beats CEL-SCI on 5 of the 8 factors compared between the two stocks. Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$12.01M$276.34M$5.55B$20.85BDividend YieldN/AN/A3.75%3.65%P/E Ratio-8.25N/A28.0127.56Price / SalesN/A430.80432.8159.11Price / CashN/A22.4436.1622.29Price / Book26.409.998.124.66Net Income-$26.92M-$110.10M$3.25B$994.58M7 Day Performance12.18%0.42%1.68%-0.29%1 Month Performance72.93%15.99%7.30%4.90%1 Year Performance-90.08%20.34%32.89%11.14% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCI0.1789 of 5 stars$3.96-5.0%N/A-90.4%$12.01MN/A-8.2543High Trading VolumeCOEPCoeptis Therapeutics0.1865 of 5 stars$7.73+2.5%N/A+79.8%$26.49M$62.87K-1.332TPSTTempest Therapeutics1.5958 of 5 stars$7.08-0.7%$30.00+323.7%-75.1%$26.26MN/A-0.3920NRSNNeuroSense Therapeutics2.0802 of 5 stars$2.09+9.4%$14.00+569.9%+168.4%$26.10MN/A-3.8710CVKDCadrenal Therapeutics2.9635 of 5 stars$12.95-0.2%$32.00+147.1%N/A$25.53MN/A-1.404Positive NewsCGTXCognition Therapeutics3.1172 of 5 stars$0.58+42.9%$2.83+389.5%-66.3%$25.11MN/A-0.7820High Trading VolumeALXOALX Oncology3.1419 of 5 stars$0.44-3.5%$3.30+643.2%-92.3%$24.57MN/A-0.1840CARACara Therapeutics0.2372 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580News CoverageGap DownHigh Trading VolumeTENXTenax Therapeutics1.2455 of 5 stars$5.75-1.0%$17.50+204.3%+79.5%$24.10MN/A-2.329Gap UpOVIDOvid Therapeutics4.6781 of 5 stars$0.37+10.5%$3.13+735.6%-42.6%$24.06M$570K-1.0760Analyst UpgradeGap UpHigh Trading VolumeCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809 Related Companies and Tools Related Companies Coeptis Therapeutics Competitors Tempest Therapeutics Competitors NeuroSense Therapeutics Competitors Cadrenal Therapeutics Competitors Cognition Therapeutics Competitors ALX Oncology Competitors Cara Therapeutics Competitors Tenax Therapeutics Competitors Ovid Therapeutics Competitors Cyclo Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CVM) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CVM Stock Alerts